Cytokinetics (CYTK)
NASDAQ:CYTK
Want to see CYTK full AI Analyst Report?
CYTK Stock Chart & Stats
$66.71
-$0.99(-2.05%)
At close: 4:00 PM EST
$66.71
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$31.99 - $80.20
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.45M
Market Cap
$10.23B
Enterprise Value$10.88B
Total Cash (Recent Filing)$818.55M
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Jul 30, 2026EPS Estimate
-1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.83
Shares Outstanding124,432,560
10 Day Avg. Volume2,250,274
30 Day Avg. Volume2,447,722
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-11.56
Price to Sales (P/S)86.62
P/FCF Ratio-14.26
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue102.81
Enterprise Value/Gross Profit113.79
Enterprise Value/Ebitda-14.81
Forecast
1Y Price Target
$104.20Price Target Upside56.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-6.39
Revenue Forecast (FY)$107.99M
Bulls Say, Bears Say
Bulls Say
Commercial Launch TractionRecording initial product revenue and early prescriber uptake demonstrates that Cytokinetics can convert clinical programs into commercial sales. Durable metrics (prescribers, REMS certifications, rapid paid conversion) indicate a nascent recurring revenue stream and validated commercial capabilities beyond one-off milestones.
Regulatory Approval And EU ExpansionEU approval and an imminent German launch materially broaden addressable markets and diversify revenue sources. Ongoing HTA submissions and multi‑jurisdiction filings create structural optionality for sustained international sales and reduce single‑market dependency over the medium term.
Material Capital Raise Strengthens RunwayA large equity infusion materially extends financial runway, lowering near‑term refinancing risk and enabling continued launch investment and late‑stage trials. This reduces the immediate need for dilutive or expensive debt and supports execution of commercialization and regulatory milestones.
Bears Say
Elevated Leverage And Negative EquityHigh debt combined with negative equity signals an imbalanced capital structure that reduces financial flexibility. Persistent losses could force future dilutive financings or costly refinancing, constraining long‑term strategic options and increasing stakeholder risk over the next several quarters.
Substantial Ongoing Cash BurnLarge negative operating and free cash flows indicate the business is not self‑funding and requires external capital to sustain launches and trials. Even with recent financing, persistent cash burn elevates execution risk and the probability of future fundraising if revenue ramps or cost reductions lag expectations.
Safety Observations In Pivotal TrialNotable LVEF declines and serious heart‑failure events in Acacia HCM create durable regulatory and prescriber uncertainty. These safety signals may narrow label, require risk‑management measures, or limit uptake among higher‑risk patients, affecting long‑term market penetration and revenue potential.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $31.99 and its highest was $80.20 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $10.23B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on May 05, 2026. The company reported -$1.67 earnings per share for the quarter, missing the consensus estimate of -$1.652 by -$0.018.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.64.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 124,432,560 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.67 in its last earnings report, missing expectations of -$1.652. Following the earnings report the stock price went down -2.919%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$104.20 (56.20% Upside)
$104.20 (56.20% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 766.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.37%
12-Months-Change
Fundamentals
Return on Equity
139.66%
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Company Deck
CYTK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple major positive developments: first commercial launch with encouraging early uptake and revenue, EU approval and imminent German launch, positive pivotal Acacia HCM topline results that could expand aficamtin to nonobstructive HCM, and continued pipeline progress and regulatory filings. Offsetting these positives are meaningful launch and operating costs (SG&A up sharply), continued cash burn, incomplete payer access early in launch, and notable safety observations in Acacia HCM (higher incidence of LVEF decline and a small number of serious heart failure events) that will require regulatory and prescriber scrutiny. On balance, the transformative commercial and clinical milestones materially outweigh the near-term financial and safety challenges described on the call.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$104.20
▲(56.20% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
0.81% Insiders
37.56% Mutual Funds
10.21% Other Institutional Investors
27.17% Public Companies and
Individual Investors